Search Results
14 protocol(s) meet the specified criteria
100305Open  
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

100314Open  
Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

108914Open  
First-In-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax®-AXL-ADC) in Patients with Solid Tumors

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

90521Open  
Phase II, Multicenter, Four-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (WT), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

94144Open  
Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

95241Open  
Phase II, Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

95965Open  
Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) versus Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

97412Open  
Open-Label Phase I/II Study of INCB039110 in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

97414Open  
Randomized, Open-Label, Phase III Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors